Imatinib (IM) is utilized for targeting the BCR–ABL fusion protein and as such, chronic myeloid leukemia (CML) is considered to be a curable disorder for which patients can achieve a long survival. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.